AML relapse after rituximab treatment for GvHD: crucial role for B cells in GvL responses

Bone Marrow Transplant. 2016 Sep;51(9):1245-8. doi: 10.1038/bmt.2016.90. Epub 2016 Apr 18.

Authors

M A Gillissen^{1

2}, G de Jong^{1

2}, S E Levie¹, E Yasuda¹, A Q Bakker¹, L M Evers², S T Pals³, C Huisman², P M van Helden¹, H Spits¹, M D Hazenberg²

Affiliations

¹ AIMM Therapeutics, Academic Medical Center, Amsterdam, The Netherlands.
² Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands.
³ Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands.

PMID: 27088384
DOI: 10.1038/bmt.2016.90

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
B-Lymphocytes / immunology
B-Lymphocytes / physiology
Fatal Outcome
Graft vs Host Disease / drug therapy*
Graft vs Host Disease / etiology
Graft vs Leukemia Effect / drug effects
Hematopoietic Stem Cell Transplantation / adverse effects
Humans
Leukemia, Myeloid, Acute / complications
Leukemia, Myeloid, Acute / pathology*
Leukemia, Myeloid, Acute / therapy
Male
Recurrence
Rituximab / adverse effects*
Transplantation, Homologous

Substances

Rituximab